Arena Pharmaceuticals Inc. (ARNA) Sees Significant Decline in Short Interest

Josh Kim
December 18, 2016

AGIO has been the topic of a number of research analyst reports.

08/19/2016 - BTIG Research began new coverage on Agios Pharmaceuticals, Inc. giving the company a "neutral" rating.

Shares of Arena Pharmaceuticals (NASDAQ:ARNA) opened at 1.46 on Friday.

FBR Capital Markets began new coverage on Arena Pharmaceuticals, Inc. giving the company a "outperform" rating.

11/28/2016 - Oppenheimer began new coverage on Agios Pharmaceuticals, Inc. giving the company a "perform" rating. Zacks Investment Research downgraded shares of Agios Pharmaceuticals from a "hold" rating to a "sell" rating in a report on Wednesday, October 5th. One investment analyst has rated the stock with a sell rating, four have issued a hold rating and three have given a buy rating to the company's stock.

The consensus analyst recommendation is 2.70 on Arena Pharmaceuticals, Inc. The company had a trading volume of 4,104,500 shares. Arena Pharmaceuticals, Inc. has a 52-week low of 1.30 and a 52-week high of 2.16. The firm has a 50-day moving average price of $1.50 and a 200 day moving average price of $1.66. The stock's market capitalization is $1.89 billion.

Microsoft Surface Pro 5 Could Represent the Company's Biggest Launch in 2017
Microsoft is also set to roll out its next significant update to Windows 10, also-known-as Windows 10 Redstone 2 by spring 2017. As for the device's accessories, the Surface Pro 5 should come with an improved Surface Pen.

Based on Agios Pharma's latest earnings report for the quarter ending September 30, the company posted quarterly revenue of $8.99 million and GAAP net loss of $62.83 million. The firm earned $19.20 million during the quarter, compared to analysts' expectations of $13.99 million. The firm's revenue was up 111.0% compared to the same quarter past year.

03/01/2016 - Arena Pharmaceuticals, Inc. had its "sector perform" rating reiterated by analysts at RBC Capital.

COPYRIGHT VIOLATION NOTICE: "Agios Pharmaceuticals Inc".

05/18/2016 - Agios Pharmaceuticals, Inc. had its "buy" rating reiterated by analysts at SunTrust. If you are viewing this news story on another domain, it was stolen and reposted in violation of United States & worldwide copyright and trademark law. Needham & Company LLC began coverage on shares of Agios Pharmaceuticals in a report on Monday. The comany was founded by Lewis Clayton Cantley, Tak W. Mak, Craig B. Thompson and Shin-Shan Michael Su on August 7, 2007 and is headquartered in Cambridge, MA. The shares were sold at an average price of $54.15, for a total value of $33,952.05. Sell-side analysts are projecting a short term price target of $3.75 on the shares. (NASDAQ:AGIO) by 40.8% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. They now have a Dollars 9 price target on the stock. BlackRock Advisors LLC now owns 126,164 shares of the biopharmaceutical company's stock valued at $221,000 after buying an additional 6,721 shares during the last quarter. The disclosure for this sale can be found here. Company insiders own 10.55% of the company's stock.

Hedge funds have recently modified their holdings of the stock. Public Employees Retirement Association of Colorado increased its position in shares of Agios Pharmaceuticals by 1.4% in the second quarter. Price T Rowe Associates Inc. Public Employees Retirement Association of Colorado raised its stake in shares of Agios Pharmaceuticals by 1.4% in the second quarter. California State Teachers Retirement System now owns 514,162 shares of the biopharmaceutical company's stock valued at $879,000 after buying an additional 1,425 shares during the last quarter. Columbus Circle Investors bought a new position in shares of Agios Pharmaceuticals during the third quarter valued at about $15,999,000. Royal Bank of Canada increased its position in shares of Agios Pharmaceuticals by 65.0% in the first quarter. BB Biotech AG now owns 2,649,528 shares of the biopharmaceutical company's stock valued at $139,948,000 after buying an additional 286,207 shares in the last quarter. Utah Retirement Systems purchased a new position in shares of Agios Pharmaceuticals during the second quarter valued at about $214,000. The fund owned 3,921 shares of the biopharmaceutical company's stock after buying an additional 1,136 shares during the period.

Other institutional investors have also added to or reduced their stakes in the company.

Other reports by MyHealthBowl

Discuss This Article

FOLLOW OUR NEWSPAPER